Clinical Trials Logo

Refractory Pediatric AML clinical trials

View clinical trials related to Refractory Pediatric AML.

Filter by:
  • None
  • Page 1

NCT ID: NCT05622591 Withdrawn - Clinical trials for Acute Myeloid Leukemia

ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML

Pediatric AML
Start date: March 2024
Phase: Phase 1
Study type: Interventional

This research study was planned to focus on a rare type of acute myeloid leukemia (with the subtype CBFA2T3::GLIS2 that overexpresses folate receptor alpha (FRĪ±) (a protein on the surface of leukemia cells)) that has relapsed or is refractory. Relapse means the cancer has come back after treatment. Refractory means the cancer does not respond to treatment.

NCT ID: NCT02638428 Recruiting - Clinical trials for Relapsed Pediatric AML

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Start date: December 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and feasibility of combination chemotherapy with target agents according to the result of targeted deep sequencing in pediatric patients with relapsed/refractory solid tumor or AML.